论文部分内容阅读
目的探讨普罗纳克滴眼液对睑板腺功能障碍(meibomian gland dysfunction,MGD)患者睑板腺分泌物中前列腺素E_2(prostaglandin E_2,PGE_2)水平的影响。方法将52例71眼MGD患者分为轻中度组和重度组。轻中度组使用普罗纳克+羟糖苷滴眼液;重度组第1周使用妥布霉素地塞米松眼膏+普罗纳克+羟糖苷滴眼液,第2周使用普罗纳克+羟糖苷滴眼液。采用酶联免疫吸附试验检测治疗前和每周用药后睑板腺分泌物中PGE_2的含量。结果与治疗前比较,轻中度组及重度组连续治疗1周、2周后睑板腺分泌物中PGE_2含量均下降,差异有统计学意义(P<0.01)。结论普罗纳克滴眼液对MGD所产生的PGE_2有抑制作用。
Objective To investigate the effects of Prognosis on the level of prostaglandin E2 (PGE_2) in meibomian gland secretion in patients with meibomian gland dysfunction (MGD). Methods Fifty-two eyes of 71 patients with MGD were divided into mild to moderate group and severe group. The mild and moderate groups were treated with propranolol + hydroxyglycoside eye drops; in the severe group, tobramycin dexamethasone eye ointment + Glycosides eye drops. Enzyme-linked immunosorbent assay was used to detect the content of PGE_2 in meibomian gland secretions before and after treatment. Results Compared with those before treatment, the contents of PGE_2 in meibomian gland secretions decreased after one week and two weeks of continuous treatment in mild to moderate group and severe group, respectively, with statistical significance (P <0.01). CONCLUSION Prionac eye drops have an inhibitory effect on PGE 2 produced by MGD.